早期类风湿关节炎疲乏改善滞后于疾病缓解:加拿大早期关节炎队列研究
该研究基于加拿大早期关节炎队列(CATCH),纳入症状持续时间≤12个月的早期RA患者,随访至5年,分析疾病活动度与疲乏的纵向关系。结果显示基线疲乏普遍,疲乏与疼痛及患者整体评估相关性较强、与DAS28等指标相关性较弱;3个月内达到DAS28<3.2者疲乏评分显著更低且改善持续至5年,疲乏的最大改善滞后缓解约6个月。
要点
- 3个月内达到DAS28<3.2者疲乏评分显著低于未达标者,且持续至5年。
- 疲乏最大改善滞后疾病缓解约6个月,需长期随访管理疲乏。
核心结论
- 早期RA中疲乏常见,疲乏改善可能发生在疾病缓解之后,3个月内早期治疗应答与短期及长期疲乏获益相关。
研究设计与样本
- 数据来自加拿大早期关节炎队列(CATCH)中症状持续时间≤12个月的早期RA患者,采用11点数字评定量表(NRS)评估近一周疲乏,随访最长5年,比较入组3个月内达到与未达到低疾病状态(DAS28<3.2)患者的疲乏评分差异。
主要发现
- 疲乏与疼痛及患者整体评估相关(r=0.56-0.67,P<0.001),与DAS28、压痛关节数、肿胀关节数、医生整体疾病活动评估、红细胞沉降率及C反应蛋白水平相关性较弱。
- 3个月时报告低疲乏者随访期间疲乏显著低于3个月时中度或高度疲乏者(P<0.001);3个月内达到DAS28<3.2者疲乏评分均值±SD为2.7±2.6,低于未达标者的4.6±3.0(P<0.001),改善持续至5年随访。
- 疲乏的最大改善滞后缓解约6个月。
关键数值与推荐
- 疲乏严重程度分级:低≤2,中度>2但<5,高度≥5(11点NRS)。
- 低疾病状态定义为DAS28<3.2。
临床怎么用
- 对早期RA应早期积极治疗以争取3个月内达到DAS28<3.2,并关注疲乏的长期随访与患者报告结局。
局限性
- 原文摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the relationship between disease activity and fatigue over time in early rheumatoid arthritis (RA). METHODS: Data were from patients with early RA (duration of symptoms ≤12 months) enrolled in the Canadian Early Arthritis Cohort (CATCH). Patients rated their fatigue over the past week using an 11-point numerical rating scale (NRS) for up to 5 years of follow-up. Fatigue severity was classified as low (≤2), moderate (>2 but <5), or high (≥5). Differences in fatigue ratings in patients who achieved a low disease state (Disease Activity Score in 28 joints [DAS28] <3.2) and those who did not within 3-months of cohort entry were compared. RESULTS: Of 1,864 patients included, 88% met RA criteria, and 72% were women. The mean ± SD baseline DAS28 was 4.9 ± 1.5. Nineteen percent of the patients reported moderate baseline fatigue, and 59% reported severe baseline fatigue. Fatigue was correlated with pain and patient global ratings (r = 0.56-0.67, P < 0.001), and was weakly correlated with DAS28, tender joint count, swollen joint count, physician global assessment of disease activity, erythrocyte sedimentation rate, and C-reactive protein level. Patients who reported low fatigue by 3 months had significantly lower fatigue throughout follow-up compared to those who had moderate or high fatigue at 3 months (P < 0.001). Patients who achieved a DAS28 <3.2 within 3 months had significantly lower fatigue ratings (mean ± SD 2.7 ± 2.6) than those with a DAS28 >3.2 (4.6 ± 3.0) (P < 0.001), with improvements in fatigue that persisted through 5 years of follow-up. Maximal improvements in fatigue lagged behind remission by 6 months. CONCLUSION: Fatigue is common in early RA, and improvements may occur after remission. Early treatment response within 3-months was associated with short-term and long-term benefits in fatigue over time.
引用
- Holdren M, Schieir O, Bartlett SJ, et al. Improvements in Fatigue Lag Behind Disease Remission in Early Rheumatoid Arthritis: Results From the Canadian Early Arthritis Cohort. Arthritis Rheumatol. 2020. PMID: 32852109. doi:10.1002/art.41499
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。